SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMRPRNewsWire • 03/09/22
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Larimar Therapeutics, Inc. (LRMR) InvestigationBusiness Wire • 02/17/22
Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare ConferenceGlobeNewsWire • 11/22/21
Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology ConferenceGlobeNewsWire • 11/15/21
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial ResultsGlobeNewsWire • 11/12/21
Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines EventGlobeNewsWire • 09/16/21
Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare ConferenceGlobeNewsWire • 09/02/21
Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug CongressGlobeNewsWire • 08/19/21
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial ResultsGlobeNewsWire • 08/12/21
Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021GlobeNewsWire • 07/08/21
Larimar Therapeutics to Present at the JMP Securities Life Sciences ConferenceGlobeNewsWire • 06/11/21
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement FinancingGlobeNewsWire • 05/25/21
Larimar Shares Trade Higher On $95M Capital Raise, CTI-1601's Priority Medicines Tag In EuropeBenzinga • 05/21/21
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich's AtaxiaGlobeNewsWire • 05/20/21
Larimar Therapeutics Reports Positive CTI-1601 Data From Friedreich's Ataxia TrialBenzinga • 05/11/21
Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich's AtaxiaGlobeNewsWire • 05/11/21
Larimar Therapeutics Reports First Quarter 2021 Operating and Financial ResultsGlobeNewsWire • 05/10/21